Found: 9
Select item for more details and to access through your institution.
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0642-0
- By:
- Publication type:
- Article
A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
- Published in:
- Biopharmaceutics & Drug Disposition, 1994, v. 15, n. 7, p. 535, doi. 10.1002/bdd.2510150702
- By:
- Publication type:
- Article
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Calmodulin binding to α<sub>1</sub>-purothionin: Soloution binding and modeling of the complex.
- Published in:
- Proteins, 1992, v. 14, n. 2, p. 127, doi. 10.1002/prot.340140202
- By:
- Publication type:
- Article
Predicted calmodulin-binding sequence in the γ subunit of phosphorylase b kinase.
- Published in:
- Proteins, 1987, v. 2, n. 1, p. 20, doi. 10.1002/prot.340020104
- By:
- Publication type:
- Article
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
- Published in:
- Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 3, doi. 10.1186/1756-8722-6-81
- By:
- Publication type:
- Article
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 21, p. 4869, doi. 10.1002/cncr.26129
- By:
- Publication type:
- Article
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 508, doi. 10.1111/bjh.12274
- By:
- Publication type:
- Article